论文部分内容阅读
资料来源:FDA网站发布时间:2012.11.2911月29日,美国FDA批准了Exelixis公司的Cabozantinib(商品Cometriq)用于治疗转移性甲状腺髓样癌,甲状腺产生的降钙素(calcitonin)有助于维持血中钙处于正常水平,在产生降钙素的细胞中发生的癌被称为甲状腺髓样癌。这种癌自发产生或发生在有某些基因突变家族,可累及内分泌系统的一个或多个器官,包括甲状腺。
Source: FDA Published: 2012.11.29 On November 29, 29, FDA approved Cabozantinib (commercial Cometriq) from Exelixis for the treatment of metastatic thyroid medullary carcinoma. The thyroid gland calcitonin helps to maintain Calcium in blood is normal, and cancers that occur in cells that produce calcitonin are called medullary thyroid carcinomas. This cancer spontaneously occurs or occurs in one or more organs, including the thyroid gland, that have a family of mutations that can affect the endocrine system.